Citigroup Inc Janux Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 15,595 shares of JANX stock, worth $848,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,595

Previous 41,572 62.49%

Holding current value

$848,212

Previous $1.57 Million 58.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$35.12 - $64.78 $912,312 - $1.68 Million	-25,977 Reduced 62.49%	15,595 $653,000
Q1 2024 May 10, 2024	BUY	$7.93 - $49.75 $299,317 - $1.88 Million	37,745 Added 986.28%	41,572 $1.57 Million
Q4 2023 Feb 09, 2024	BUY	$5.85 - $11.7 $19,521 - $39,042	3,337 Added 681.02%	3,827 $41,000
Q3 2023 Nov 09, 2023	SELL	$9.56 - $14.0 $50,639 - $74,158	-5,297 Reduced 91.53%	490 $4,000
Q2 2023 Aug 10, 2023	BUY	$11.08 - $15.92 $57,926 - $83,229	5,228 Added 935.24%	5,787 $68,000
Q1 2023 May 11, 2023	BUY	$11.25 - $22.21 $1,822 - $3,598	162 Added 40.81%	559 $6,000
Q4 2022 Feb 09, 2023	SELL	$11.1 - $18.26 $6,526 - $10,736	-588 Reduced 59.7%	397 $5,000
Q3 2022 Nov 10, 2022	SELL	$10.82 - $16.84 $12,616 - $19,635	-1,166 Reduced 54.21%	985 $13,000
Q2 2022 Aug 10, 2022	BUY	$9.52 - $15.65 $2,865 - $4,710	301 Added 16.27%	2,151 $26,000
Q1 2022 May 12, 2022	SELL	$13.24 - $20.24 $38,846 - $59,384	-2,934 Reduced 61.33%	1,850 $27,000
Q4 2021 Feb 10, 2022	BUY	$15.44 - $27.32 $46,767 - $82,752	3,029 Added 172.59%	4,784 $94,000
Q3 2021 Nov 10, 2021	BUY	$20.7 - $34.69 $36,328 - $60,880	1,755 New	1,755 $38,000

Others Institutions Holding JANX

# of Institutions

160

Shares Held

37.2M

Call Options Held

70.4K

Put Options Held

101K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account